Recce Pharmaceuticals Ltd |
High $0.63 |
Low $0.59 |
Trades 32 |
Turnover $33,720 |
Volume 55,179 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $111,633,096 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (6-Nov) 2,548 (0.00%) (632nd) |
|
52w High $0.73 |
52w Low $0.265 |
P/E - |
EPS -0.05 |
Recce Clinical Pipeline Update
RCE released this announcement to the ASX on 7 June 2021, 10:09. The announcement is marked as price sensitive, and is 3 page(s) in length and 291.67kb in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.124% short sold according to ASIC data. It was ranked the 418th most shorted stock on the ASX. It remains ranked 632nd as of the latest reported data (06 November 2026).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Recce Clinical Pipeline Update | 7 June 2021, 10:09 |
| R327 Demonstrates World First Multiple Mechanisms of Action | 27 May 2021, 13:18 |
| R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO | 19 May 2021, 13:44 |
| Positive Data on RECCE 327 Against All Six ESKAPE Pathogens | 4 May 2021, 8:19 |
If you were already registered, log in here.